Pelthos Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | $16.8M | $0 | — | — |
| Cost of Revenue | — | $4.0M | $0 | — | — |
| Gross Profit | — | $12.8M | $0 | — | — |
| Gross Margin | — | 76.3% | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | $1.2M | $1.2M | $2.6M | $391.7K |
| SG&A Expense | — | $42.5M | $6.4M | $2.7M | $1.1M |
| Operating Income | — | $-32.4M | $-7.6M | $-6.9M | $-2.3M |
| Operating Margin | — | -193.1% | — | — | — |
| Interest Expense | — | — | $581.1K | $309.1K | $135.6K |
| Pretax Income | — | $-50.7M | $-8.0M | $-7.4M | $-2.5M |
| Income Tax Expense | — | $-7.4M | $0 | — | — |
| Net Income | — | $-43.3M | $-8.0M | $-7.4M | $-2.5M |
| Net Margin | — | -257.9% | — | — | — |
| EPS (Basic) | — | $-23.04 | $-4.76 | $-1.93 | $0.63 |
| EPS (Diluted) | — | $-23.04 | $-4.76 | $-1.93 | — |
| Shares Outstanding (Basic) | 3.4M | 1.9M | 1.7M | 3.8M | 3.9M |
| Shares Outstanding (Diluted) | 3.4M | 1.9M | 1.7M | 3.8M | 3.9M |
| Dividends Per Share | — | — | — | — | — |